Literature DB >> 19574548

Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.

Junwang Xu1, Fraz A Ismat, Tao Wang, Min Min Lu, Nicole Antonucci, Jonathan A Epstein.   

Abstract

RATIONALE: Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder with a broad array of clinical manifestations, including benign and malignant tumors, and characteristic cutaneous findings. NF1 patients also have an increased incidence of cardiovascular diseases, including obstructive vascular disorders and hypertension. The disease gene, NF1, encodes neurofibromin, a ubiquitously expressed protein that acts, in part, as a Ras-GAP (GTP-ase activating protein), downregulating the activity of activated Ras protooncogenes. In animal models, endothelial and smooth muscle expression of the disease gene is critical for normal heart development and the prevention of vascular disease, respectively.
OBJECTIVE: To determine the role of NF1 in the postnatal and adult heart. METHODS AND
RESULTS: We generated mice with homozygous loss of the murine homolog Nf1 in myocardium (Nf1mKO) and evaluated their hearts for biochemical, structural, and functional changes. Nf1mKO mice have normal embryonic cardiovascular development but have marked cardiac hypertrophy, progressive cardiomyopathy, and fibrosis in the adult. Hyperactivation of Ras and downstream pathways are seen in the heart with the loss of Nf1, along with activation of a fetal gene program.
CONCLUSIONS: This report describes a critical role of Nf1 in the regulation of cardiac growth and function. Activation of pathways known to be involved in cardiac hypertrophy and dysfunction are seen with the loss of myocardial neurofibromin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574548      PMCID: PMC2747036          DOI: 10.1161/CIRCRESAHA.109.201509

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  40 in total

Review 1.  Activation of the small GTP-binding protein Ras in the heart by hypertrophic agonists.

Authors:  P H Sugden; A Clerk
Journal:  Trends Cardiovasc Med       Date:  2000-01       Impact factor: 6.677

Review 2.  NF1 tumor suppressor gene function: narrowing the GAP.

Authors:  K Cichowski; T Jacks
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

3.  Ras regulates NFAT3 activity in cardiac myocytes.

Authors:  M Ichida; T Finkel
Journal:  J Biol Chem       Date:  2000-10-23       Impact factor: 5.157

4.  Nf1 has an essential role in endothelial cells.

Authors:  Aaron D Gitler; Yuan Zhu; Fraz A Ismat; Min Min Lu; Yasutaka Yamauchi; Luis F Parada; Jonathan A Epstein
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

5.  Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain.

Authors:  Y Zhu; M I Romero; P Ghosh; Z Ye; P Charnay; E J Rushing; J D Marth; L F Parada
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

6.  The heart in neurofibromatosis type 1: an echocardiographic study.

Authors:  Michele Adolfo Tedesco; Giovanni Di Salvo; Francesco Natale; Valeria Pergola; Elvira Calabrese; Carolina Grassia; Gennaro Ratti; Diana Iarussi; Aldo Iacono; Raffaele Calabrò; Giuliana Lama
Journal:  Am Heart J       Date:  2002-05       Impact factor: 4.749

Review 7.  Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy.

Authors:  Christopher G Proud
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

8.  Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.

Authors:  Chinmay M Trivedi; Min Min Lu; Qiaohong Wang; Jonathan A Epstein
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

9.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

Authors:  T Jacks; T S Shih; E M Schmitt; R T Bronson; A Bernards; R A Weinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

Review 10.  Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force.

Authors:  J M Friedman; Jack Arbiser; Jonathan A Epstein; David H Gutmann; Stephen J Huot; Angela E Lin; Bruce McManus; Bruce R Korf
Journal:  Genet Med       Date:  2002 May-Jun       Impact factor: 8.822

View more
  25 in total

1.  Calcium-mediated histone modifications regulate alternative splicing in cardiomyocytes.

Authors:  Alok Sharma; Hieu Nguyen; Cuiyu Geng; Melissa N Hinman; Guangbin Luo; Hua Lou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation.

Authors:  Seung Tae Baek; Michelle D Tallquist
Journal:  Development       Date:  2012-04-25       Impact factor: 6.868

3.  Targeting NF2-Hippo/Yap signaling pathway for cardioprotection after ischemia/reperfusion injury.

Authors:  Masum M Mia; Ayshwarya L Chelakkot-Govindalayathil; Manvendra K Singh
Journal:  Ann Transl Med       Date:  2016-12

4.  Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.

Authors:  Jinliang Li; Michael D Kritzer; Jennifer J Carlisle Michel; Andrew Le; Hrishikesh Thakur; Marjorie Gayanilo; Catherine L Passariello; Alejandra Negro; Joshua B Danial; Behzad Oskouei; Michael Sanders; Joshua M Hare; Andre Hanauer; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  Circ Res       Date:  2012-09-20       Impact factor: 17.367

5.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.

Authors:  Xue Wu; Jeremy Simpson; Jenny H Hong; Kyoung-Han Kim; Nirusha K Thavarajah; Peter H Backx; Benjamin G Neel; Toshiyuki Araki
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

6.  Transforming growth factor Beta2 is required for valve remodeling during heart development.

Authors:  Mohamad Azhar; Kristen Brown; Connie Gard; Hwudaurw Chen; Sudarsan Rajan; David A Elliott; Mark V Stevens; Todd D Camenisch; Simon J Conway; Thomas Doetschman
Journal:  Dev Dyn       Date:  2011-07-20       Impact factor: 3.780

7.  Myeloid Cell mPges-1 Deletion Attenuates Mortality Without Affecting Remodeling After Acute Myocardial Infarction in Mice.

Authors:  Lihong Chen; Guangrui Yang; Tingting Jiang; Soon Yew Tang; Tao Wang; Qing Wan; Miao Wang; Garret A FitzGerald
Journal:  J Pharmacol Exp Ther       Date:  2019-04-16       Impact factor: 4.030

8.  Mitofusins 1 and 2 are essential for postnatal metabolic remodeling in heart.

Authors:  Kyriakos N Papanicolaou; Ryosuke Kikuchi; Gladys A Ngoh; Kimberly A Coughlan; Isabel Dominguez; William C Stanley; Kenneth Walsh
Journal:  Circ Res       Date:  2012-08-17       Impact factor: 17.367

9.  Myocardial deletion of Smad4 using a novel α skeletal muscle actin Cre recombinase transgenic mouse causes misalignment of the cardiac outflow tract.

Authors:  Mohamad Azhar; Pei-Yu Wang; Tony Frugier; Kyoko Koishi; Chuxia Deng; Peter G Noakes; Ian S McLennan
Journal:  Int J Biol Sci       Date:  2010-09-20       Impact factor: 6.580

10.  Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.

Authors:  Waqar Waheed; Muriel H Nathan; Gilman B Allen; Neil M Borden; M Ali Babi; Rup Tandan
Journal:  BMJ Case Rep       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.